The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2013Neuromelanin in Circulating Phagocytes May Reveal Early Neurodegeneration in Parkinson’s Disease
Objective/Rationale:
A normal function of inflammation is to recruit phagocytic white blood cells (think PACMAN) to clear away the damaged cells. We postulate that debris laden PACMEN re... -
Therapeutic Pipeline Program, 2013Pre-clinical Evaluation of Neuroprotective Small Molecule Erythropoietin Receptor Agonists in the Treatment of Parkinson’s Disease
Objective/Rationale:
Erythropoietin (EPO) receptor is present throughout the body and plays a role in both red blood cell production and tissue protection. STATegics has discovered small... -
Synuclein Therapeutic Acceleration Program, 2013Quinpramine for Parkinson’s Disease
Objective/Rationale:
A part of Parkinson’s disease progression involves abnormal aggregation of normal brain proteins into knots of insoluble irritant material. The protein involved in... -
Therapeutic Pipeline Program, 2013Development of Trehalose as a Disease-modifying Treatment for Parkinson’s Disease
Objective/Rationale:
The development of Parkinson’s disease (PD) is linked to the accumulation of the toxic protein alpha-synuclein. Systems within neurons able to clear alpha-synuclein... -
Biosample and Tissue Resource, 2013From Genetic Risk Toward Genetic Prognosis
Objective/Rationale:
The progression and prognosis of Parkinson’s disease (PD) varies considerably between individual patients — ranging from a manageable, functional decline to an aggressive course... -
Research Grant, 2013Development of Highly Sensitive Immunoassays for pS129 Alpha-synuclein in Human Samples
Objective/Rationale:
The development of disease-modifying therapies in Parkinson’s disease requires the availability of quantitative biomarkers for use in primary diagnosis, monitoring...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.